Detalles de la búsqueda
1.
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
Gastroenterology
; 162(7): 1876-1890, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35122766
2.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35227777
3.
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Gastroenterology
; 159(1): 139-147, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32224129
4.
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
Gut
; 69(4): 658-664, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31285357
5.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Lancet
; 390(10114): 2779-2789, 2017 12 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29096949
6.
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
Am J Gastroenterol
; 113(6): 872-882, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29867173
7.
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.
Gastrointest Endosc
; 83(1): 188-97.e1-3, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26234693
8.
Clinical disease activity in the CALM study - Authors' reply.
Lancet
; 391(10129): 1482, 2018 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29676280
9.
Nitrate and nitrite in biology, nutrition and therapeutics.
Nat Chem Biol
; 5(12): 865-9, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19915529
10.
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria.
Proc Natl Acad Sci U S A
; 105(39): 15064-9, 2008 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-18806221
11.
A mammalian functional nitrate reductase that regulates nitrite and nitric oxide homeostasis.
Nat Chem Biol
; 4(7): 411-7, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18516050
12.
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
J Crohns Colitis
; 14(2): 254-266, 2020 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31403666
13.
A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool.
J Crohns Colitis
; 2020 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32722760
14.
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials.
J Crohns Colitis
; 13(9): 1227-1233, 2019 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30726897
15.
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
J Crohns Colitis
; 13(6): 725-734, 2019 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30753371
16.
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
Inflamm Bowel Dis
; 25(9): 1522-1531, 2019 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30753510
17.
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
J Crohns Colitis
; 12(8): 930-938, 2018 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29697818
18.
Protection from nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers by dietary nitrate.
Free Radic Biol Med
; 42(4): 510-8, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17275683
19.
Nitrite in saliva increases gastric mucosal blood flow and mucus thickness.
J Clin Invest
; 113(1): 106-14, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-14702114
20.
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
J Crohns Colitis
; 11(4): 425-434, 2017 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815351